In early November, Sui will unlock a tranche of tokens ranging from 2.07 million to 22.6 million SUI, representing up to 0.55% of the circulating supply. This unlock is part of a long-term vesting schedule with a 12-month cliff and 72 months of linear vesting, meaning only a small monthly portion becomes tradable rather than a large sudden release. The token price is around $0.96, down about 5% over the past week, with a market cap near $3.96 billion. The unlock's impact on price is expected to be limited as the amounts are small relative to daily trading volume, and holders should consider their own holding periods and leverage positions. German investors should note that tax obligations depend on individual holding periods, not the unlock date.
The Sui token unlock schedule is the subject, providing context for readers interested in cryptocurrency market conditions. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 24, 2026 13:31 WIB: out of 50 major cryptocurrencies, 6 rose and 43 fell today. Notable movers include GRT (The Graph) at Rp422 with a 1-day change of -4.19% and a typical hold time of 99 days, UNI (Uniswap) at Rp125,030 with a 1-day change of -4.16% and a typical hold time of 65 days, and SNX (Synthetix) at Rp3,710 with a 1-day change of -3.79% and a typical hold time of 70 days. Pluang order activity shows 28% sell and 72% buy for GRT, 52% sell and 48% buy for UNI, and 0% sell and 100% buy for SNX.
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
Early Ethereum investors sold a total of 4,000 ETH from two wallets, with one ICO participant selling 1,000 ETH and another holder offloading 3,000 ETH worth $7.23 million. This activity coincides with Santiment's report of the largest daily net ETH ...
Immatics presented encouraging clinical data for its IMA402 PRAME bispecific and IMA203CD8 PRAME cell therapies at the 2026 ESMO Annual Meeting. IMA402 showed a 32% confirmed objective response rate (cORR) in advanced melanoma patients with high PRAM...
Eli Lilly's investigational drug sofetabart mipitecan (Sofe-M), combined with bevacizumab, achieved a 79% confirmed objective response rate and 100% disease control rate in a Phase 1 study involving platinum-sensitive ovarian cancer patients. The tre...
Zymeworks presented new Phase 1 data for ZW191, an antibody-drug conjugate targeting folate receptor alpha, showing a 64.5% confirmed response rate at the 6.4 mg/kg dose in heavily pretreated patients with platinum-resistant ovarian cancer. The treat...
